Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13D
 
Under the Securities Exchange Act of 1934
(Amendment No. ________)*
 
La Jolla Pharmaceutical Company
(Name of Issuer)
 
Common
(Title of Class of Securities)
 
503459307
(CUSIP Number)
 
Greiner Joseph Advisory Group 16141 Swingley Ridge Road, Suite 212, Chesterfield, MO 63017
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
 
 
(Date of Event which Requires Filing of this Statement)
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨
 
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
 
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 
 
 
         
CUSIP No. 503459307
  
13D
  
Page 2 of 4 Pages
         

         
1.
  
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Richard Reinisch
    
2.
  
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨
    
3.
  
SEC USE ONLY
 
    
4.
  
SOURCE OF FUNDS (see instructions)
 
 
    
5.
  
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)
or 2(e)     ¨
    
6.
  
CITIZENSHIP OR PLACE OF ORGANIZATION
 
US
    
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7.
  
SOLE VOTING POWER
 
1,100,000
8.
  
SHARED VOTING POWER
 
00000
9.
  
SOLE DISPOSITIVE POWER
 
1,100,000
10.
  
SHARED DISPOSITIVE POWER
 
00,000
11.
  
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
1,100,000
    
12.
  
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions)    ¨
 
    
13.
  
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
8.3%
    
14.
  
TYPE OF REPORTING PERSON (see instructions)
 
IN
    
 
 
 
 
 
         
CUSIP No. 503459307
  
13D
  
Page 3 of 4 Pages
         
         
 
Item 1. Security and Issuer.
   
  La Jolla Pharmaceutical Company
   
Item 2. Identity and Background.
   
Item 3. Source or Amount of Funds or Other Consideration.
   
Item 4. Purpose of Transaction.
   
Item 5. Interest in Securities of the Issuer.
   
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
   
Item 7. Material to Be Filed as Exhibits.
 
 
 
 
 
         
CUSIP No. 503459307
  
13D
  
Page 4 of 4 Pages
         
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
   
 
COMPANY NAME
   
 
/s/ Richard Reinischs
  Richard Reinisch
   
 
Insert Title
  Individual
   
 
Insert Date
  03/21/2013